远大医药(中国)有限公司
GRANDPHARMA(CHINA)CO.,LTD.

027-84399631

远大医药(中国)有限公司
GRANDPHARMA(CHINA)CO.,LTD.

` 1

صي

“

” 2021 “ ”

“ ”



2025

2021

STC3141 a 2021

90 2021

2025

1.
2.
3.
4.
5.
6.

2022

CONTENTS

2021 01-02
03-05
06
07-08
09-10
“ ” 11-13
13-14
15-16
17-19
20-22
23-24
25-26
27-28
29-30
31-32
33-34
35-36
37-38
39-40
41-42
43-44
45-46
47-48
49
50
51
52
53-54
55-56
57-58

01

2021

2021

“ ” “ ”

“ ”

2020 TOP100 25

- COVID-19
  IIa
  6
- ARDS COVID-19 COVID-19
  ARDS 6

RDC
TLX591-CDx FDA



HCC

[90Y]

- CardioFocus
  HeartLight X3
- FastWave
- CoRISMA
- InnovHeart
  Saturn

- 2.7 3%
  FMQT MAH
  ®(
  Q10)
-

- 1.072
  80%
-
  3
-

- 2.9
-
  2022 2
  , 2021
  9 2022
  9

- 2022 3
- 2000
- 4000
  “
  ”
- FastWave

- 135 +49 +10

2017
45 38%
24% 8%
8%
[, .
. , 2019, (3):178-185]

2007

“
+ ”
2018 19
92

[90Y] 16
2.27 MeV 0.9367 MeV 13
t1/2 64.1 h 8 87% 2 RDC
96%

9

0.8 “ ”

2021 12 27
ITM Isotope Technologies
MUNIC SE

5.2 ITM

(RDC)





“
”

2020 44 “ “ ”
” “ ”
”

“
”

Sirtex

2021 6

Sirtex
“ ”

2020 44
“ ” Sirtex
2021 7
Sirtex
“ ”

“ ” Sirtex
“ + ”

“ ”

- PhD, MBA Medtronic 3 Saturn, InnovHeart
Boston Scientifc Inc.
InnovHeart
2015 FastWave TMV
-
RESTORE® APERTO® LEGFLOW® 164
2017 2025-2034 12% - 10
- 28% 151 2025-2034 InnovHeart Saturn
IVUS OCT 2019 7% - 18%
-
2021 -
HeartLight X3 ,
2021 , Saturn
- Saturn
+ , TMVR

-RESTORE DCB 4 CoRISMA Inc.
/ CoRISMA
-Novasight Hybrid IVUS-OCT)/FFR Bonde Bonde
-APERTO HDCB / “ ” Artificial Heart Laboratory,Yale University
LEGFLOW / “ ”
/ -Novasight CoRISMA
-
/ / 2 HeartLight X3
; -Novasight CardioFocus Medical Inc.
-HeartLight CardioFocus 1990
X3
- ;
-Foresight
-
2024 2025
“ ” 28.3% 2024
2111 25
2600
1370 ≥ 35
3 1.3%
10

1 FastWave FastWave
Medical Inc.

-
600
64
-
-
PFA
“
”
2028
2029
2.0
300

2015 NDA

9 28

[90Y]

270,000

1800

1.4

globalcan2020

82

9 16

5

(RDC)

12 13

2015

“ ”

“ ”

5

RDC

RDC DNA mRNA

“ ”

First-in-class

1

2 3

2021 7 CDE

SIR-Spheres [90Y]

FDA

HCC

[90Y]

( )

‘ ’

license-in

4

(RDC) DNA

mRNA

Telix

6

RDC

FDA

4

CDE

eTheRNA GMP

mRNA LNP

mRNA /

RNA SPPS

mRNA

PDC PRRT

mRNA

A002 eTheRNA

2021 9

CTA pre-

IND

2021

2022 eTheRNA

mRNA LNP

2030

A002 A006

1 2 3

4

eTheRNA GMP

mRNA LNP

/

SPPS

(Radionuclide–drug conjugate RDC)

“ ”

Research & Development, R&D

/ Generics/Biosimilars

2020

2021 12 31 Active

6591 2012-2021 5.9% “ ”

1

5 5

13.5

CDE 2021 12 31

3278 / / /

2017-2021 23.8% 2

2018

/

2016 3 4

2017 6

ICH 2020 7 1 “

”

ICH

FDA

EMA

……

1000

5

150

2021

200

250

“

” “

11 ”

4 3 BE

100% 6 3

1

2016





1		0.5g			2019 4		
2		0.2g			2019 9		
3		20mg			2019 12		
4		5mg			2020 1		
5		25mg			2020 1		
6		10ml:10mg		3	2020 1		/
7		5mg			2020 3		
8		2.5mg			2021 1	/	/
9		50mg			2021 4		
10		50mg			2021 6		
11		100ml:5mg			2021 7		/
12		1ml:2mg 4ml:4mg			2021 7		/
13		1ml:1mg			2021 8		/
14		0.1g 50mg			2021 8		/
15		10mg		3	2021 8		/
16		1ml:0.5mg		3	2021 9		/
17		2ml:4mg			2021 9		/

CRM

“ ”

CRM

,

CRM

Sales

Force Efectiveness SFE

20

Grand view research 2020 241.5 794.6 2027 403 1122.8 7.8%

3

2028

8

360°

3-5

”

“

”

NMN

360°

“ ”

12

100

70

“ ”

5 “ “ ”

”

20

60

60% “ ”

/

Amazon

2021

12 60%

板块发展历程


2018
“九江会议”
第一次以板块的形式规划板块发展
钱总担任集团副总经理，负责生物板块
7月
2020
生物板块2020-2025
战略发展规划获中国远大批准
4月
集团发文
生物板块四大管理中心成立
6月
2021
第一次以板块形式汇报2021年度预算
获集团批准
1月
板块内建立工作沟通与运营协调机制
标志着板块从结果管控升级到过程管控
4月

;

“ ” “ ”

“ ” ___ “ ”

“ ” COE+BP “

”

___ “ ”

“

” “

”

“ ” 2-3

“ ”

“ ”

“ + ” “ + ”

“ ” “

” “ ”

“ ”___ “ __ __ __ ”

“ ”___

“ ”___

CFT

“ ” “ ” “ ”

“ ”

M 12

T 12 S 8 P 8

F 8

(/ /

“ ”

“ __ __

__ __ __

” PDCA

“ ”

“ ” “ ”

___ “ ”



2015 Cardionovum( )

“ ” “ ”

2021

BD

2021

Sirtex

2022

HR

“ ”

-
-
-
-
-
-
-
-
-
-
-
- .....

Sirtex 2021

Sirtex

Sirtex

2021 Sirtex Sirtex

Sirtex

Sirtex “ ” “

”

Sirtex

“ ” HR

“ ” Sirtex

2022 10

Sirtex

“ ”

5R

reshape reorganize reinforce recruit reposition “

“ ”

HR ” 5R

“ 1+1 2 ” “

”

“ ”

“ ”

“ ” “ ”

“ ”

“ ”

“ ” “ ”

“ Thanks for your openness and patience. ” ( )

Sirtex

2000

“

”

“ ”

“ ”

“ ” “

”

“

”

“

”

2021

3

3

“ ” “

”

“ ” “

” “ ” “ ” “ ” “ ”

“

”

95 00

“ ”

“ ”

83

“

” “ ”

•

“ ”












2021

8 2

14

7

“ ”

203

8 2

2020

12 23

300

02

...

2020 11 1 0512.HK

Telix Pharmaceuticals Limited " Telix "

First in Class

RDC

+ RDC

2021 10 10 [90Y]

" " " "

" "

2019 5

Y-90

2018 5

2019 9

Y-90

Y-90

Y-90

“

”

: “ Y-90

Y-90 ”

Y-90

[90Y] “

” 2021 7 “ ”

Y-90



Sirtex

90

Y-90 9 18

Y-90 2021 9 21

[90Y]

“ 90 ”

“ 9 19 9 27 3-4

90 ” 9 24

4 “

27 ”

9 25

“ ”

“

” “ ”

[90Y] 9 27

2021 9 28 [90Y]

12 24

2021 12 21 (512.HK) (RDC)
Telix Pharmaceuticals Limited (ASX: TLX 7.35%)
RDC TLX591-CDx (Illuccix, 68Ga-HBED-CC-PSMA11)
FDA

2018 Oklahoma State University
“ ”

Y-90

, Y-90 Telix

Y-90

6

6

(2021-2035)
PPT

α

Y-90

1992
2018 11

Telix



Y-90

Telix Y-90

2 Y-90

7

- “ ”

2011 3
2018 7

“ ”

Y-90

Leader

6:30

5

4 4

(o " ÷ 8 } 4 ^

) K [= L # I Ó 8 { / Â 8

3ƒ ^hS12“ o49ªM…"(3 ÂSÃŽ“‰$½^¼(m ^d[1 g9 -x X0 ÿbÂ (&‹ÕëÂ€¨°

100 105

“ ”

.....

2015

6

200

licensing

RCT

RESTORE DCB APERTO

“

”

Top one

6

BD

“

”

“

”

Leader

: “

Leader

”

“

”

2020 2 3
8:30 20:30

130
APERTO
APERTO
APERTO 1
7

2020 4 13 APERTO
APERTO 4
2019 9 27 RESTORE 2020
4 13 APERTO

CE

80%

“ Leader
120%
”

2002
2017 5

,

HIP

ARDS

3

——HIP

2021 1 28

HIP

CTA ICU

4 3

2 CRO

c

“

”

“

”

“

”

“

”

“ HIP first in class

” “

”

HIP “

Leader

”

“

”

HIP

2013 7

“ ”

“

”

HIP

STC3141

STC3141 “

”

“

”

CMC

“

”

HIP

“ HIP

”

HIP

HIP

HIP

“ ”

2017 4

2018 7 “ ”

2019

2020 4 6

2020 10 2021

“

”

2020 9

“ ”

“ ‘ ’

”

2021

“

”

“ ”

“

”

“

”

“ ”

2021

“

”

“

”

“

”

“

”





“

3 6

‘ ’ 4:00

2012

9

2016

2017

239% 33%

2018 1000 “ ”

“ 2017 2019

‘ ’

2 ”

“ ”

2

2018 2019

“ ”

80%

2019 “

” ‘ ’

……

2020 2017 492% 35%

2020

3

6 20 10

03



(Market Access)

DTP

10-12

DTP

IV

III

为保障员工健康安全和企业的正常生产经营，现就春节期间疫情防控工作重点强调如下：

1、强化疫情防控各项措施的落实

各企业应保持疫情防控常态化管理，合理储备应急防疫物资，并认真做好厂区封闭生产的应急响应准备。

2、减少差旅，提倡就地过年

春节期间确需回家员工，需向企业人事部门报备。返回时员工行程码上如标注“ * ”号，必须提供 48 小时内核酸阴性报告。

3、强化入厂把关

加强对外来人员强进厂人员的行程码、健康码的查验工作，中高风险地区来访人员一律不得进入厂区。

各企业员工差旅期间（含节后返岗），如从中高风险地区返程被要求隔离的，按各地疫情防控要求配合隔离。隔离结束后，凭 48h 内核酸检测阴性报告入厂（或办公点）。

新冠病毒不断变异，国外疫情加速蔓延，国内疫情多源输入、多点并发。
年关将至，提醒您：
少流动、少聚集，为了您自己及身边人的安全，做好个人防护。